NASDAQ:PACB - Pacific Biosciences of California Stock Price, Price Target & More

Get Started

$2.53 -0.05 (-1.94 %)

(As of 05/27/2018 10:03 AM ET)

Previous Close$2.53

Today's Range$2.4350 - $2.6052

52-Week Range$2.02 - $5.70

Volume723,397 shs

Average Volume814,543 shs

Market Capitalization$333.65 million

P/E RatioN/A

Dividend YieldN/A

Beta1.58

About Pacific Biosciences of California (NASDAQ:PACB)

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company's single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes single molecule biochemical reactions in real time. The company also provides consumable products, including SMRT cells, as well as various reagent kits, such as template preparation, binding, and sequencing kits. Its customers include research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. The company markets its products through a direct sales force in North America and Europe, as well as primarily through distribution partners in Asia, the Middle East, and Latin America. The company was formerly known as Nanofluidics, Inc. Pacific Biosciences of California, Inc. was founded in 2000 and is headquartered in Menlo Park, California.

Receive PACB News and Ratings via Email

Sign-up to receive the latest news and ratings for PACB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Analytical instruments

Sub-IndustryLife Sciences Tools & Services

SectorMedical

SymbolNASDAQ:PACB

CUSIP69404D10

Webwww.pacb.com

Phone650-521-8000

Debt

Debt-to-Equity Ratio0.14

Current Ratio4.64

Quick Ratio3.60

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$93.47 million

Price / Sales3.57

Cash FlowN/A

Price / CashN/A

Book Value$0.78 per share

Price / Book3.24

Profitability

EPS (Most Recent Fiscal Year)($0.87)

Net Income$-92,180,000.00

Net Margins-105.22%

Return on Equity-91.11%

Return on Assets-58.10%

Miscellaneous

Employees456

Outstanding Shares131,880,000

Pacific Biosciences of California (NASDAQ:PACB) Frequently Asked Questions

What is Pacific Biosciences of California's stock symbol?

Pacific Biosciences of California trades on the NASDAQ under the ticker symbol "PACB."

How were Pacific Biosciences of California's earnings last quarter?

Pacific Biosciences of California (NASDAQ:PACB) issued its earnings results on Wednesday, May, 2nd. The biotechnology company reported ($0.20) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.19) by $0.01. The biotechnology company earned $19.40 million during the quarter, compared to the consensus estimate of $23.97 million. Pacific Biosciences of California had a negative net margin of 105.22% and a negative return on equity of 91.11%. The firm's revenue for the quarter was down 22.1% on a year-over-year basis. During the same period in the previous year, the company posted ($0.26) EPS. View Pacific Biosciences of California's Earnings History.

When is Pacific Biosciences of California's next earnings date?

Pacific Biosciences of California is scheduled to release their next quarterly earnings announcement on Tuesday, July, 31st 2018. View Earnings Estimates for Pacific Biosciences of California.

What price target have analysts set for PACB?

2 equities research analysts have issued 12 month price targets for Pacific Biosciences of California's shares. Their predictions range from $4.00 to $6.80. On average, they anticipate Pacific Biosciences of California's share price to reach $5.40 in the next year. View Analyst Ratings for Pacific Biosciences of California.

Who are some of Pacific Biosciences of California's key competitors?

Some companies that are related to Pacific Biosciences of California include Accelerate Diagnostics (AXDX), Quanterix (QTRX), Fluidigm (FLDM), Harvard Bioscience (HBIO), pSivida (EYPT), HTG Molecular Diagnostics (HTGM), Aethlon Medical (AEMD), Arrayit Corp common stock (ARYC), Precipio (PRPO), Pressure Biosciences (PBIO), Scientific Industries (SCND) and PositiveID (PSID).

Who are Pacific Biosciences of California's key executives?

Pacific Biosciences of California's management team includes the folowing people:

Dr. Michael W. Hunkapiller, Exec. Chairman, CEO & Pres (Age 69)
Ms. Susan K. Barnes, Sr. VP & CFO (Age 64)
Mr. James Michael Phillips, Sr. VP of R&D (Age 67)
Mr. Kevin P. Corcoran, Sr. VP of Market Devel. (Age 59)
Ms. Kathy P. Ordoñez, Chief Commercial Officer, Exec. VP & Director (Age 67)

Has Pacific Biosciences of California been receiving favorable news coverage?

Media stories about PACB stock have been trending somewhat positive on Sunday, Accern Sentiment reports. The research group identifies positive and negative news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Pacific Biosciences of California earned a daily sentiment score of 0.16 on Accern's scale. They also assigned news stories about the biotechnology company an impact score of 45.16 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

Who are Pacific Biosciences of California's major shareholders?

Pacific Biosciences of California's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.67%), Blackstone Group L.P. (3.13%), Point72 Asset Management L.P. (1.59%), Northern Trust Corp (1.00%), Trellus Management Company LLC (0.59%) and Schwab Charles Investment Management Inc. (0.39%). View Institutional Ownership Trends for Pacific Biosciences of California.

Which institutional investors are selling Pacific Biosciences of California stock?

PACB stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN. View Insider Buying and Selling for Pacific Biosciences of California.

Which institutional investors are buying Pacific Biosciences of California stock?

PACB stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Blackstone Group L.P., BlackRock Inc., Citadel Advisors LLC, Millennium Management LLC, UBS Group AG, Trellus Management Company LLC and Northern Trust Corp. View Insider Buying and Selling for Pacific Biosciences of California.

How do I buy shares of Pacific Biosciences of California?

Shares of PACB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pacific Biosciences of California's stock price today?

One share of PACB stock can currently be purchased for approximately $2.53.

How big of a company is Pacific Biosciences of California?

Pacific Biosciences of California has a market capitalization of $333.65 million and generates $93.47 million in revenue each year. The biotechnology company earns $-92,180,000.00 in net income (profit) each year or ($0.87) on an earnings per share basis. Pacific Biosciences of California employs 456 workers across the globe.

How can I contact Pacific Biosciences of California?

Pacific Biosciences of California's mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-521-8000 or via email at [email protected]

MarketBeat Community Rating for Pacific Biosciences of California (PACB)

Community Ranking:		2.4 out of 5 ( )
Outperform Votes:		188 (Vote Outperform)
Underperform Votes:		204 (Vote Underperform)
Total Votes:		392

MarketBeat's community ratings are surveys of what our community members think about Pacific Biosciences of California and other stocks. Vote "Outperform" if you believe PACB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PACB will underperform the S&P 500 over the long term. You may vote once every thirty days.

Pacific Biosciences of California (NASDAQ:PACB) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

2 Wall Street analysts have issued ratings and price targets for Pacific Biosciences of California in the last 12 months. Their average twelve-month price target is $5.40, suggesting that the stock has a possible upside of 113.44%. The high price target for PACB is $6.80 and the low price target for PACB is $4.00. There are currently 2 hold ratings for the stock, resulting in a consensus rating of "Hold."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Hold	Hold
Consensus Rating Score:	2.00	2.33	2.33	2.33
Ratings Breakdown:	0 Sell Rating(s) 2 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$5.40	$6.2667	$6.2667	$6.2667
Price Target Upside:	113.44% upside	55.50% upside	55.50% upside	55.50% upside

Pacific Biosciences of California (NASDAQ:PACB) Consensus Price Target History

Price Target History for Pacific Biosciences of California (NASDAQ:PACB)

Pacific Biosciences of California (NASDAQ:PACB) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
11/3/2017	First Analysis	Downgrade	Overweight ➝ Equal Weight	$4.00	N/A
9/28/2017	CL King	Downgrade	Buy ➝ Neutral	$6.80	High
4/27/2017	Cantor Fitzgerald	Set Price Target	Buy	$8.00	Medium
11/3/2016	JPMorgan Chase & Co.	Reiterated Rating	Hold	$12.00	N/A

(Data available from 5/27/2016 forward)

Pacific Biosciences of California (NASDAQ:PACB) Earnings History and Estimates Chart

Earnings by Quarter for Pacific Biosciences of California (NASDAQ:PACB)

Pacific Biosciences of California (NASDAQ:PACB) Earnings Estimates

2018 EPS Consensus Estimate: ($0.66)
2019 EPS Consensus Estimate: ($0.46)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	2	($0.19)	($0.19)	($0.19)
Q2 2018	2	($0.18)	($0.18)	($0.18)
Q3 2018	2	($0.17)	($0.15)	($0.16)
Q4 2018	2	($0.13)	($0.13)	($0.13)
Q1 2019	1	($0.14)	($0.14)	($0.14)
Q2 2019	1	($0.13)	($0.13)	($0.13)
Q3 2019	1	($0.10)	($0.10)	($0.10)
Q4 2019	1	($0.09)	($0.09)	($0.09)

Pacific Biosciences of California (NASDAQ PACB) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
7/31/2018		($0.17)					N/A
5/2/2018	Q1 2018	($0.19)	($0.20)	$23.97 million	$19.40 million	View	Listen
2/1/2018	Q4 2017	($0.1960)	($0.18)	$21.89 million	$24.94 million	View	Listen
11/2/2017	Q3 2017	($0.20)	($0.19)	$28.29 million	$23.54 million	View	N/A
8/2/2017	Q2 2017	($0.24)	($0.26)	$23.34 million	$20.07 million	View	Listen
4/26/2017	Q1 2017	($0.23)	($0.26)	$23.80 million	$24.90 million	View	N/A
2/2/2017	Q416	($0.23)	($0.21)	$22.84 million	$25.70 million	View	Listen
11/2/2016	Q316	($0.20)	($0.19)	$24.68 million	$25.10 million	View	N/A
8/4/2016	Q2	($0.22)	($0.21)	$20.19 million	$20.70 million	View	N/A
4/21/2016	Q1	($0.25)	($0.23)	$18.02 million	$19.10 million	View	Listen
2/3/2016	Q4	($0.02)	($0.02)	$36.96 million	$36.28 million	View	N/A
10/22/2015	Q3	($0.27)	$0.02	$15.84 million	$13.90 million	View	Listen
8/5/2015	Q215	($0.14)	($0.16)	$26.36 million	$24.94 million	View	Listen
5/5/2015	Q115	($0.27)	($0.27)	$13.70 million	$17.65 million	View	N/A
2/3/2015	Q414	($0.26)	($0.26)	$14.90 million	$16.90 million	View	Listen
10/23/2014	Q214	($0.16)	($0.13)	$17.20 million	$20.60 million	View	Listen
7/24/2014	Q114	($0.15)	($0.27)	$11.39 million	$11.40 million	View	N/A
4/30/2014		($0.28)	($0.28)	$10.17 million	$11.64 million	View	N/A
2/4/2014	Q413	($0.27)	($0.26)	$9.13 million	$9.10 million	View	N/A
10/22/2013	Q313	($0.30)	($0.31)	$7.08 million	$7.40 million	View	N/A
8/1/2013	Q2 2013	($0.35)	($0.33)	$6.09 million	$6.04 million	View	N/A
4/23/2013	Q1 2013	($0.37)	($0.37)	$4.28 million	$5.60 million	View	N/A
2/5/2013	Q4 2012	($0.37)	($0.39)	$4.38 million	$5.90 million	View	N/A
10/25/2012		($0.45)	($0.41)			View	N/A
7/26/2012		($0.46)	($0.40)			View	N/A
5/1/2012		($0.47)	($0.50)			View	N/A
2/7/2012		($0.50)	($0.42)			View	N/A
10/27/2011	Q3 2011	($0.60)	($0.45)			View	N/A
8/4/2011		($0.63)	($0.42)			View	N/A
4/27/2011		($0.67)	($0.66)			View	N/A
2/15/2011		($0.91)	($0.97)			View	N/A
11/30/2010	Q3 2010		($39.70)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Pacific Biosciences of California (NASDAQ:PACB) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Pacific Biosciences of California (NASDAQ PACB) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 13.40%
Institutional Ownership Percentage: 70.49%

Insider Trading History for Pacific Biosciences of California (NASDAQ:PACB)

Institutional Ownership by Quarter for Pacific Biosciences of California (NASDAQ:PACB)

Pacific Biosciences of California (NASDAQ PACB) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/28/2016	James Michael Phillips	SVP	Sell	20,000	$8.44	$168,800.00	201,449
7/29/2016	James Michael Phillips	SVP	Sell	20,000	$8.45	$169,000.00	198,949
4/25/2016	James Michael Phillips	SVP	Sell	20,000	$10.29	$205,800.00	201,449
3/2/2015	Brian B Dow	VP	Buy	2,503	$4.91	$12,289.73
3/2/2015	Kevin P Corcoran	SVP	Buy	2,816	$4.91	$13,826.56
8/19/2014	William W Ericson	Director	Buy	39,299	$5.14	$201,996.86
8/18/2014	William W Ericson	Director	Buy	135,155	$5.09	$687,938.95
8/14/2014	William W Ericson	Director	Buy	77,822	$5.00	$389,110.00
8/13/2014	William W Ericson	Director	Buy	29,435	$4.93	$145,114.55
8/12/2014	William W Ericson	Director	Buy	123,423	$4.89	$603,538.47
12/12/2013	Michael Hunkapiller	CEO	Buy	100,000	$4.13	$413,000.00	1,800,000
11/21/2013	Michael Hunkapiller	CEO	Buy	200,000	$3.61	$722,000.00	1,700,000
12/3/2012	Michael Hunkapiller	CEO	Buy	154,100	$1.75	$269,675.00
11/29/2012	Michael Hunkapiller	CEO	Buy	242,200	$1.68	$406,896.00
11/26/2012	Michael Hunkapiller	CEO	Buy	186,400	$1.44	$268,416.00
11/20/2012	Michael Hunkapiller	CEO	Buy	155,000	$1.27	$196,850.00
11/16/2012	Michael Hunkapiller	CEO	Buy	262,300	$1.16	$304,268.00
8/7/2012	Michael Hunkapiller	CEO	Buy	400,000	$1.75	$700,000.00

(Data available from 1/1/2013 forward)

Pacific Biosciences of California (NASDAQ PACB) News Headlines

Source:

Date	Headline
	Research Analysts Issue Forecasts for Pacific Biosciences of California's Q2 2018 Earnings (PACB) www.americanbankingnews.com - May 25 at 6:35 AM
	Analyzing Mettler-Toledo International (MTD) & Pacific Biosciences of California (PACB) www.americanbankingnews.com - May 23 at 9:20 PM
	Phase Genomics and Pacific Biosciences Announce the Release of Co-Developed Genome Assembly Phasing Software - 'FALCON-Phase' www.prnewswire.com - May 21 at 8:51 PM
	Pacific Biosciences (PACB) Expected to Announce Quarterly Sales of $24.05 Million www.americanbankingnews.com - May 19 at 4:19 AM
	Pacific Biosciences (PACB) versus Bruker (BRKR) Critical Contrast www.americanbankingnews.com - May 17 at 11:16 PM
	Zacks: Analysts Expect Pacific Biosciences (PACB) Will Post Earnings of -$0.16 Per Share www.americanbankingnews.com - May 17 at 10:17 AM
	The Clock Is Ticking Louder As PacBio Must Generate More Revenue And Shrink Its Cash Burn Rate seekingalpha.com - May 15 at 5:02 PM
	pSivida (EYPT) & Pacific Biosciences (PACB) Critical Review www.americanbankingnews.com - May 15 at 10:46 AM
	Pacific Bio (PACB) Announces Favorable Outcome in UK and German Patent Litigation Against Oxford Nanopore www.streetinsider.com - May 9 at 9:17 AM
	Pacific Biosciences Announces Favorable Outcome in UK and German Patent Litigation Against Oxford Nanopore finance.yahoo.com - May 9 at 9:17 AM
	Research Analysts Set Expectations for Pacific Biosciences' Q4 2018 Earnings (PACB) www.americanbankingnews.com - May 7 at 4:18 AM
	Here's Why Pacific Biosciences of California Is Falling Today finance.yahoo.com - May 3 at 4:36 PM
	For Pacific Biosciences of California, a First Quarter Hurt by Shipment Delays finance.yahoo.com - May 3 at 4:36 PM
	Here's Why Pacific Biosciences of California Is Falling Today www.fool.com - May 3 at 1:21 PM
	Benzinga's Daily Biotech Pulse: Achaogen Slumps On Mixed FDA Panel Vote, Pacific Biosciences Sinks On Q1 Miss feeds.benzinga.com - May 3 at 9:36 AM
	Pacific Biosciences of California's (PACB) CEO Mike Hunkapiller on Q1 2018 Results - Earnings Call Transcript seekingalpha.com - May 3 at 9:06 AM
	Edited Transcript of PACB earnings conference call or presentation 2-May-18 8:30pm GMT finance.yahoo.com - May 3 at 9:06 AM
	Pacific Biosciences: 1Q Earnings Snapshot finance.yahoo.com - May 3 at 9:06 AM
	Pacific Biosciences (PACB) Upgraded to Sell by ValuEngine www.americanbankingnews.com - May 2 at 10:58 PM
	Pacific Biosciences (PACB) Announces Earnings Results, Misses Expectations By $0.01 EPS www.americanbankingnews.com - May 2 at 10:02 PM
	Pacific Biosciences of California, Inc. Announces First Quarter 2018 Financial Results finance.yahoo.com - May 2 at 4:43 PM
	$24.58 Million in Sales Expected for Pacific Biosciences (PACB) This Quarter www.americanbankingnews.com - May 1 at 2:20 AM
	Zacks: Analysts Expect Pacific Biosciences (PACB) Will Post Earnings of -$0.19 Per Share www.americanbankingnews.com - April 29 at 7:20 PM
	Cracking the Code of Life—at Light Speed www.wsj.com - April 28 at 4:36 PM
	Pacific Biosciences (PACB) Set to Announce Quarterly Earnings on Wednesday www.americanbankingnews.com - April 25 at 9:50 AM
	GENEWIZ And Pacific Biosciences Announce Winner Of The 2017 Structural Variant SMRT® Grant Program finance.yahoo.com - April 24 at 4:52 PM
	Next Generation Sequencing (NGS) Global Market 2018-2023 to Grow at a CAGR of 20.21% www.prnewswire.com - April 23 at 4:35 PM
	Can Core Unit Drive Pacific Biosciences' (PACB) Q1 Earnings? www.msn.com - April 20 at 9:23 AM
	Pacific Biosciences (PACB) Scheduled to Post Quarterly Earnings on Tuesday www.americanbankingnews.com - April 17 at 2:49 AM
	Pacific Biosciences (PACB) Receives Average Recommendation of "Hold" from Analysts www.americanbankingnews.com - April 16 at 1:44 AM
	Pacific Biosciences (PACB) Stock Rating Lowered by BidaskClub www.americanbankingnews.com - April 15 at 12:35 PM
	Head to Head Contrast: Pacific Biosciences (PACB) versus Integra lifesciences (IART) www.americanbankingnews.com - April 15 at 7:21 AM
	Pacific Biosciences (PACB) Expected to Announce Quarterly Sales of $24.23 Million www.americanbankingnews.com - April 14 at 2:21 AM
	BidaskClub Upgrades Pacific Biosciences (PACB) to "Hold" www.americanbankingnews.com - April 13 at 10:45 AM
	Pacific Biosciences Gains as HudsonAlpha Picks Sequel System finance.yahoo.com - April 13 at 9:33 AM
	Short Interest in Pacific Biosciences (PACB) Decreases By 19.4% www.americanbankingnews.com - April 13 at 3:23 AM
	Pacific Biosciences (PACB) Expected to Post Earnings of -$0.19 Per Share www.americanbankingnews.com - April 12 at 7:21 PM
	Pacific Biosciences (PACB) Upgraded to "Sell" by BidaskClub www.americanbankingnews.com - April 12 at 6:14 PM
	Pacific Biosciences (PACB) Downgraded to Hold at Zacks Investment Research www.americanbankingnews.com - April 12 at 11:07 AM
	Pacific Biosciences (PACB) Upgraded at Zacks Investment Research www.americanbankingnews.com - April 11 at 9:52 AM
	HudsonAlpha Using PacBio Sequencing for Childhood Developmental Disabilities Research finance.yahoo.com - April 11 at 9:51 AM
	Pacific Biosciences: A Shovel Supplier To The Genomics Megatrend seekingalpha.com - April 10 at 4:40 PM
	Genome Sequencing Roundup seekingalpha.com - April 2 at 4:40 PM
	Zacks: Brokerages Anticipate Pacific Biosciences of California (PACB) Will Post Quarterly Sales of $24.23 Million www.americanbankingnews.com - March 28 at 2:50 AM
	Pacific Biosciences Announces Ten-Unit Sequel System Order for Annoroad finance.yahoo.com - March 27 at 9:38 AM
	Pacific Biosciences of California (PACB) Expected to Post Earnings of -$0.19 Per Share www.americanbankingnews.com - March 26 at 9:12 PM
	Health Care Sector Update for 03/23/2018: PACB, PGNX, PFE, GSK, VTVT - Nasdaq www.nasdaq.com - March 23 at 4:40 PM
	Pacific Biosciences Prevails in Patent Eligibility Ruling Against Oxford Nanopore - GlobeNewswire (press release) globenewswire.com - March 22 at 4:41 PM
	Pacific Biosciences Prevails in Patent Eligibility Ruling Against Oxford Nanopore finance.yahoo.com - March 22 at 4:41 PM
	Pacific Biosciences of California (PACB) Receives Average Recommendation of "Hold" from Analysts www.americanbankingnews.com - March 22 at 1:52 AM

Pacific Biosciences of California (NASDAQ:PACB) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Pacific Biosciences of California (NASDAQ:PACB) Income Statement, Balance Sheet and Cash Flow Statement

Pacific Biosciences of California (NASDAQ PACB) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff